2026-526670-16-00RecruitingPhase 1
Drug-drug interaction study of midazolam and brensocatib
Source: EU CTIS (euclinicaltrials.eu) · Last updated 28 Sept 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (estimated)
- First submitted
- 10 Aug 2026
- Start date
- 6 Oct 2026
- Lead sponsor
- Insmed Inc.
- Diseases
- Cystic fibrosis
- EU CT number
- 2026-526670-16-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 26
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 64 to study how midazolam and brensocatib act together. The condition listed is non-cystic fibrosis bronchiectasis.
- Age
- 18 to 64 years
- Sex
- All sexes can join.
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmaceutical Research Associates Group B.V. | Groningen | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.